Platform-level execution plan for scaling from 150 beds (3 hospitals) to 1,000 beds over 5 years via acquisition-led single-specialty roll-up. $40M platform capital, operating playbook, specialty verticals, 5-year M&A roadmap, leadership & integration model, risk framework, and IPO exit strategy.
NASA Hospitals' core thesis: India's secondary-care hospital market is highly fragmented with 10,000+ independent 50–150 bed hospitals, many operating under financial distress due to debt burden, management inefficiency, and reliance on general-practitioner clinical positioning. Corporate chains like Apollo and Max have consolidated the top tier of the market (tertiary, 300+ bed multi-specialty) but the mid-market specialty segment remains structurally under-professionalised.
NASA acquires these distressed assets at deep discounts (8–10× EBITDA vs sector 15–16×), applies a specialty-first operational playbook, and consolidates into a 1,000-bed platform over 5 years. The exit is IPO or strategic sale at stabilised sector multiples of 16–18×, producing a 2.0–3.0× bid-ask arbitrage on platform creation alone — before any organic EBITDA growth is layered in.
Crucially, capital is deployed into operations and consolidation — not real estate. NASA leases hospital real estate (rather than owning it) to maintain high ROCE. This asset-light posture is what differentiates NASA from traditional hospital operators and supports the 25-30% ROCE target.
NASA's operating playbook deploys five integrated levers in sequence at each newly-acquired hospital:
| Phase | Timing | Lever | EBITDA Impact |
|---|---|---|---|
| 1. Stabilisation | Months 0–6 | Debt refinancing (18% → 12% rate). RPT vendor markup elimination. Governance & compliance upgrade. | +15–25% margin expansion |
| 2. Procurement | Months 3–9 | Integrate with NASA central procurement for pharma, consumables, medical devices. | 12% cost reduction |
| 3. Specialty Focus | Months 6–12 | Shift case mix from general to single-specialty (Neuro, Spine, Ortho, or CC). Recruit specialty clinicians. Rebrand. | ARPOB +30–40% |
| 4. Occupancy Lift | Months 9–18 | Referral engine from NASA network. Targeted insurance empanelment. Specialty-specific marketing. | Occupancy 60% → 75% |
| 5. Cross-Sell | Months 12+ | Tertiary referrals to other NASA hospitals (e.g., Ortho patient needing Spine care). | Incremental ARPOB lift |
| Specialty | Clinical Programs | Target ARPOB | Key Clinician Profile |
|---|---|---|---|
| Neuro | Neurology, Neurosurgery, Stroke Care, Neuro-Intervention | ₹55–75K / day | DM Neuro · MCh Neurosurgery |
| Spine | Spine Surgery, Minimally Invasive Procedures, Pain Management | ₹65–85K / day | MS Ortho · Spine Fellowship |
| Ortho | Joint Replacement, Sports Medicine, Trauma | ₹45–65K / day | MS Ortho · Joint Replacement |
| Critical Care | ICU, Emergency Medicine, Trauma, High-Acuity Services | ₹35–55K / day | MD Critical Care · EM |
Each NASA hospital specialises in one or two of the four verticals based on local market demand, existing clinical infrastructure, and clinician availability. For example: the Hyderabad Remedy hospital will focus on Neuro + Spine reflecting the region's demand profile and existing neurosurgery infrastructure. A typical platform at 500-bed scale would have 3–4 Neuro/Spine hospitals, 2–3 Ortho hospitals, and 1–2 Critical Care flagships.
| Year | Acquisitions | Bed Count | Platform EBITDA | Key Milestone |
|---|---|---|---|---|
| FY26 (now) | — | 150 | ₹6.8 Cr | Remedy acquisition close |
| FY27 | +1 acquisition (80 beds) | 230 + NASA's 300 = 530 combined | ₹18–22 Cr | Remedy stabilisation + 2nd acquisition |
| FY28 | +2 acquisitions (~150 beds) | 680 | ₹25–30 Cr | Regional platform (Hyderabad + 1 other city) |
| FY29 | +2 acquisitions (~160 beds) | 840 | ₹35–45 Cr | Exit readiness; pre-IPO scale |
| FY30 (Exit) | +1 (final) | 1,000 | ₹50–60 Cr | IPO or strategic sale at 16–18× EBITDA |
Roll-up assumption: NASA acquires similar distressed 50–70 bed hospitals at 8–10× EBITDA (vs sector 15–16×), replicates the turnaround playbook, and aggregates to the 1,000-bed target. Acquisitions staggered at ~2 per year to allow integration capacity. Central shared services (finance, HR, procurement, clinical governance) scale across the portfolio at minimal marginal cost.
NASA's operating model is structured as a centralised platform with de-centralised clinical delivery:
Integration timeline per acquisition: 100-day dedicated PMO with monthly KPI tracking. Full integration (all five operating levers deployed) targets Month 18.
Primary exit path: IPO in FY29–FY30 at 500–1,000 bed scale. Comparable benchmark: Medanta's pre-IPO (₹500 Cr revenue, 16× EBITDA multiple). At ₹27–50+ Cr stabilised EBITDA and 16–18× multiple, NASA targets exit EV of ₹430–900 Cr.
Secondary path: Strategic sale to a large Indian hospital chain (Apollo, Max, Fortis, Narayana, Manipal) seeking to add specialty beds in NASA's regional footprint. Strategic buyers typically pay 14–17× EBITDA for platform acquisitions.
Use of exit proceeds: Return all invested capital (~$40M) plus promote to LPs. Management carry typical 20% above 8% preferred return hurdle.
5-year roll-up P&L trajectory, platform-level EBITDA build, return scenarios, and IPO exit math on the Platform Financials page.